Anocca AB
Swedish biotech developing non-viral TCR‑T immunotherapies for hard-to-treat solid tumors; operates an integrated discovery and development platform (AnoccaOS), in-house cGMP manufacturing, a broad preclinical portfolio and the VIDAR-1 Phase I/II multi-asset umbrella trial targeting mutant KRAS in pancreatic cancer.
Finanzierungsrunden
1
Gesamtvolumen
€46.0 Mio.
Letzte Runde
Other
Investoren
3
Finanzierung nach Stage
Finanzierungsrunden
| Stage | Betrag | Investoren | Datum |
|---|---|---|---|
| Other | €46.0 Mio. | 21. Aug. 2025 |
